Mark J. Ratain to Pharmacogenomic Testing
This is a "connection" page, showing publications Mark J. Ratain has written about Pharmacogenomic Testing.
Connection Strength
1.751
-
Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer. 2022 Apr 15; 128(8):1649-1657.
Score: 0.190
-
Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application. Pharmacogenomics J. 2021 12; 21(6):691-711.
Score: 0.184
-
Patient insights on features of an effective pharmacogenomics patient portal. Pharmacogenet Genomics. 2020 12; 30(9):191-200.
Score: 0.175
-
Assessment of Patient Knowledge and Perceptions of Pharmacogenomics Before and After Using a Mock Results Patient Web Portal. Clin Transl Sci. 2020 01; 13(1):78-87.
Score: 0.161
-
Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation. Pharmacogenomics J. 2020 02; 20(1):126-135.
Score: 0.161
-
The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care. Clin Pharmacol Ther. 2019 12; 106(6):1179-1183.
Score: 0.160
-
Pharmacogenomic considerations for medications in the perioperative setting. Pharmacogenomics. 2019 07; 20(11):813-827.
Score: 0.159
-
Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation. Pharmacogenet Genomics. 2017 05; 27(5):179-189.
Score: 0.137
-
Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program. Clin Pharmacol Ther. 2017 07; 102(1):106-114.
Score: 0.136
-
Implementation of pharmacogenomics into inpatient general medicine. Pharmacogenet Genomics. 2023 02 01; 33(2):19-23.
Score: 0.050
-
Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). Pharmacogenet Genomics. 2021 12 01; 31(9):215-220.
Score: 0.047
-
Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis. Clin Exp Rheumatol. 2021 Nov-Dec; 39(6):1385-1393.
Score: 0.044
-
Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J. 2019 12; 19(6):528-537.
Score: 0.039
-
Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study. Pharmacogenet Genomics. 2019 02; 29(2):31-38.
Score: 0.039
-
A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). Clin Pharmacol Ther. 2019 03; 105(3):738-745.
Score: 0.038
-
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900.
Score: 0.032